Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2V617F mutation

Coexistance of JAK2V617F mutation and BCR/ABL translocation in one patient Aynı hastada JAK2V617F mutasyonu ve BCR/ABL translokasyonu birlikteliği

1Sema Hospital, Department of Hematology, İstanbul; 2Erciyes University Department of Hematology, Kayseri; 3Fatih University Department of Hematology, Ankara, 4Hacettepe University Department of Hematology, Ankara; 5Dışkapı Yıldırım Beyazıt Education and Research Hospital, Department of Hematology, Ankara, Turkey Yazışma Adresi /Correspondence: Burak Uz MD Hacettepe University Medical School, D...

Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative disorders

bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment.

Essential thrombocythemia, polycythemia vera, and myelofibrosis with myeloid metaplasia constitute the "classic" bcr/abl-negative myeloproliferative disorders (MPDs). Each of these MPDs represents a stem cell-derived clonal myeloproliferation with the respective features of thrombocytosis, erythrocytosis, and bone marrow fibrosis. Unlike with cases of chronic myeloid leukemia, in which the bcr/...

Two Cases of Myeloproliferative Neoplasm with a Concurrent JAK2V617F Mutation and BCR/ABL Translocation without Chronic Myelogenous Leukemia Phenotype Acquisition during Hydroxyurea Treatment

Sang Hyuk Park, M.D., Hyun-Sook Chi, M.D., Young-Uk Cho, M.D., Seongsoo Jang, M.D., Chan-Jeoung Park, M.D., Dae-Young Kim, M.D., Je-Hwan Lee, M.D., and Kyoo-Hyung Lee, M.D. Department of Laboratory Medicine, University of Ulsan, College of Medicine and Asan Medical Center; Department of Internal Medicine, Division of Hematology, University of Ulsan, College of Medicine and Asan Medical Center, ...

THE SIMULTANEOUS OCCURRENCE OF THE BCR-ABL TRANSLOCATION AND THE Jak2V617F MUTATION. DETECTION AND DYNAMICS EVOLUTION IN A CASE OF CHRONIC MYELOPROLIFERATIVE NEOPLASM

Although the discovery of the BCR-ABL transcript and of the Jak2 V617F mutation lead to important clarifications, the pathogenesis of chronic myeloproliferative neoplasms remains extremely complex and still presents several unknowns. Our study reports the case of a 52 years old man with chronic myeloid leukemia (BCR-ABL positive) who, after 4 years of targeted therapy with tyrosine kinase inhib...